HUTCHMED (China) Limited (HCM)
USD 13.7
(9.34%)
USD 13.7
(9.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 436.23 Million USD | -16.59% |
| 2022 | 522.99 Million USD | 22.71% |
| 2021 | 426.21 Million USD | 80.5% |
| 2020 | 236.12 Million USD | 24.44% |
| 2019 | 189.75 Million USD | 17.86% |
| 2018 | 161 Million USD | 35.53% |
| 2017 | 118.8 Million USD | 11.46% |
| 2016 | 106.58 Million USD | 38.07% |
| 2015 | 77.19 Million USD | 187.34% |
| 2014 | 26.86 Million USD | 16.08% |
| 2013 | 23.14 Million USD | -75.73% |
| 2012 | 95.35 Million USD | 9.38% |
| 2011 | 87.17 Million USD | 5.72% |
| 2010 | 82.46 Million USD | 15.32% |
| 2009 | 71.5 Million USD | 10.05% |
| 2008 | 64.98 Million USD | 37.21% |
| 2007 | 47.35 Million USD | 37.26% |
| 2006 | 34.5 Million USD | 18.33% |
| 2005 | 29.15 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 48.24 Million USD | 30.68% |
| 2024 Q2 | 76.53 Million USD | 58.63% |
| 2023 Q2 | 76.17 Million USD | 0.0% |
| 2023 Q4 | 36.91 Million USD | 0.0% |
| 2023 FY | 436.23 Million USD | -16.59% |
| 2023 Q1 | 76.17 Million USD | 215.05% |
| 2023 Q3 | 36.91 Million USD | -51.53% |
| 2022 FY | 522.99 Million USD | 22.71% |
| 2022 Q4 | 24.17 Million USD | 0.0% |
| 2022 Q3 | 24.17 Million USD | -90.75% |
| 2022 Q2 | 261.48 Million USD | 952.86% |
| 2022 Q1 | 24.83 Million USD | 108.29% |
| 2021 Q4 | -299.55 Million USD | -1232.81% |
| 2021 FY | 426.21 Million USD | 80.5% |
| 2021 Q3 | 26.44 Million USD | -73.03% |
| 2021 Q1 | 79.81 Million USD | -22.41% |
| 2021 Q2 | 98.03 Million USD | 22.82% |
| 2020 Q4 | 102.87 Million USD | 1102.93% |
| 2020 FY | 236.12 Million USD | 24.44% |
| 2020 Q2 | 58.58 Million USD | 36.97% |
| 2020 Q1 | 42.77 Million USD | 131.11% |
| 2020 Q3 | 8.55 Million USD | -85.4% |
| 2019 Q1 | 47.26 Million USD | -42.17% |
| 2019 Q2 | 48.35 Million USD | 2.31% |
| 2019 FY | 189.75 Million USD | 17.86% |
| 2019 Q3 | 14.91 Million USD | -69.15% |
| 2019 Q4 | -137.5 Million USD | -1021.78% |
| 2018 Q3 | 26.12 Million USD | -40.2% |
| 2018 Q2 | 43.69 Million USD | 8.41% |
| 2018 Q1 | 40.3 Million USD | -37.44% |
| 2018 FY | 161 Million USD | 35.53% |
| 2018 Q4 | 81.72 Million USD | 212.76% |
| 2017 FY | 118.8 Million USD | 11.46% |
| 2017 Q3 | 4.98 Million USD | -90.64% |
| 2017 Q4 | 64.41 Million USD | 1191.69% |
| 2017 Q1 | 232.99 Thousand USD | -98.13% |
| 2017 Q2 | 53.26 Million USD | 22759.33% |
| 2016 Q1 | 1.12 Million USD | -95.44% |
| 2016 FY | 106.58 Million USD | 38.07% |
| 2016 Q2 | 1.12 Million USD | 0.0% |
| 2016 Q4 | 12.44 Million USD | 0.0% |
| 2016 Q3 | 12.44 Million USD | 1002.84% |
| 2015 Q3 | 29 Million USD | 596.36% |
| 2015 FY | 77.19 Million USD | 187.34% |
| 2015 Q4 | 24.74 Million USD | -14.68% |
| 2015 Q2 | 4.16 Million USD | 0.0% |
| 2015 Q1 | 4.16 Million USD | 163.53% |
| 2014 FY | 26.86 Million USD | 16.08% |
| 2014 Q4 | -6.55 Million USD | -132.54% |
| 2014 Q2 | 681 Thousand USD | 0.0% |
| 2014 Q1 | 681 Thousand USD | -98.0% |
| 2014 Q3 | 20.15 Million USD | 2859.32% |
| 2013 Q3 | 5.49 Million USD | 415.52% |
| 2013 Q1 | 1.06 Million USD | 0.05% |
| 2013 Q2 | 1.06 Million USD | 0.0% |
| 2013 FY | 23.14 Million USD | -75.73% |
| 2013 Q4 | 33.99 Million USD | 518.33% |
| 2012 FY | 95.35 Million USD | 9.38% |
| 2012 Q3 | 1.06 Million USD | 0.0% |
| 2012 Q4 | 1.06 Million USD | 0.0% |
| 2011 FY | 87.17 Million USD | 5.72% |
| 2010 FY | 82.46 Million USD | 15.32% |
| 2009 FY | 71.5 Million USD | 10.05% |
| 2008 FY | 64.98 Million USD | 37.21% |
| 2007 FY | 47.35 Million USD | 37.26% |
| 2006 FY | 34.5 Million USD | 18.33% |
| 2005 FY | 29.15 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -5185.808% |
| Alpha Teknova, Inc. | 45.85 Million USD | -851.244% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -122.586% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -872.558% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -174.001% |
| Cosmos Health Inc. | 26.18 Million USD | -1566.226% |
| Journey Medical Corporation | 54.59 Million USD | -699.046% |
| Embecta Corp. | 528.4 Million USD | 17.443% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -60.44% |
| Dynavax Technologies Corporation | 219.14 Million USD | -99.06% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 26.063% |
| Pacira BioSciences, Inc. | 326.37 Million USD | -33.659% |
| PainReform Ltd. | 9.58 Million USD | -4451.659% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -3223.799% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -3223.799% |
| SCYNEXIS, Inc. | 51.84 Million USD | -741.365% |
| Safety Shot Inc | 12.1 Million USD | -3502.329% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -14113.238% |
| Procaps Group, S.A. | 199.47 Million USD | -118.687% |
| Theratechnologies Inc. | 72.75 Million USD | -499.581% |
| Harrow Health, Inc. | 89.97 Million USD | -384.847% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -4518.156% |
| Biofrontera Inc. | 39.95 Million USD | -991.696% |
| DURECT Corporation | 43.71 Million USD | -897.898% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 17.538% |
| Cronos Group Inc. | 96.7 Million USD | -351.076% |
| OptiNose, Inc. | 85.1 Million USD | -412.598% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -87.93% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1014.17% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 4662.609% |
| Organogenesis Holdings Inc. | 314.13 Million USD | -38.868% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -4382.976% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -913.535% |
| Radius Health, Inc. | 265.92 Million USD | -64.04% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -3051.524% |
| ProPhase Labs, Inc. | 37.85 Million USD | -1052.465% |
| Phibro Animal Health Corporation | 260.29 Million USD | -67.589% |
| Procaps Group S.A. | 187.24 Million USD | -132.973% |
| Alvotech | 285.43 Million USD | -52.829% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -4340.01% |
| Viatris Inc. | 5.96 Billion USD | 92.688% |
| Rockwell Medical, Inc. | 15.37 Million USD | -2737.459% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -628.996% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1878.998% |
| Tilray Brands, Inc. | 251.35 Million USD | -73.55% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -789.577% |
| Shineco, Inc. | 17.94 Million USD | -2330.522% |
| PetIQ, Inc. | 192.72 Million USD | -126.349% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -10829.99% |
| Incannex Healthcare Limited | 30.05 Million USD | -1351.539% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 72.676% |
| Alimera Sciences, Inc. | 62.64 Million USD | -596.399% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -57111.223% |
| Assertio Holdings, Inc. | 368.58 Million USD | -18.353% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -7311.872% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -2349.562% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1960.707% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1973.135% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -164.437% |
| Hempacco Co., Inc. | 7.59 Million USD | -5642.565% |
| Talphera, Inc. | 11.99 Million USD | -3537.077% |
| Alvotech | 285.43 Million USD | -52.829% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -210.013% |
| Lantheus Holdings, Inc. | 344.9 Million USD | -26.48% |
| Currenc Group, Inc. | 24 Million USD | -1717.471% |
| Kamada Ltd. | 45.42 Million USD | -860.311% |
| Indivior PLC | 911 Million USD | 52.115% |
| Evoke Pharma, Inc. | 12.4 Million USD | -3415.259% |
| Flora Growth Corp. | 10.57 Million USD | -4023.556% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1973.135% |
| Evolus, Inc. | 189.75 Million USD | -129.887% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -183.021% |
| Akanda Corp. | 3.48 Million USD | -12422.75% |